Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01975142 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. (NCT01975142)

Trial Description
Patients with metastatic breast cancer considered HER2 negative are included are screened for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor cell is detected, patients are treated by ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in a single ar phase II with an adaptive design.

This trial is sponsored by Institut Curie. [1]

Study Data

  • Condition: Metastatic Breast Cancer: HER2 Negative on Primary Tumor
  • Interventions:
    • Drugs used in this trial
  • Phase: II
  • Estimated Enrollment: 480
  • Start: October 2013
  • Estimated Primary Completion: November 2016
  • Last verified: October 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar